Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AMIT BHANVADIA

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1861751083
CMS profile
6575304
Location
ANAHEIM, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$1,186.58

56 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,186.58 56

By paying entity

PY2022 · entire year · sorted by reported total

Page 2 of 2; records 51–56 of 56 matching records. This page contains 6 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AMIT BHANVADIA

NPI 1861751083 · CMS profile ID 6575304

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

ANAHEIM, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–56 of 56 matching records. This page contains 6 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1861751083?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AMIT BHANVADIA, NPI 1861751083, CMS profile ID 6575304. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–56 of 56 matching records. This page contains 6 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1861751083?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). AMIT BHANVADIA, NPI 1861751083, CMS profile ID 6575304. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–56 of 56 matching records. This page contains 6 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1861751083?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
AMIT BHANVADIA, NPI 1861751083, CMS profile ID 6575304, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–56 of 56 matching records. This page contains 6 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1861751083?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

56 matching records · $1,186.58 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 56 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–56 of 56.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Nestle HealthCare Nutrition Inc. $19.5201/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 902769429 CMS
ABBVIE INC. $24.8501/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890607453 CMS
Takeda Pharmaceuticals U.S.A., Inc. $15.9001/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955594575 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $16.7501/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959844110 CMS
ABBVIE INC. $16.4201/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890607451 CMS
QOL Medical, LLC $15.5701/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904147817 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $600.93 10
PY2020 $685.85 38
PY2021 $949.07 47
PY2022 $1,186.58 56
PY2023 $571.35 28
PY2024 $855.44 32
PY2025 $626.60 26

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $388.40 1
PY2025 Principal investigator $654,493.09 232
PY2024 Recipient $16,260.55 2
PY2024 Principal investigator $593,611.97 110
PY2023 Principal investigator $386,555.18 106
PY2022 Principal investigator $42,522.20 20

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

233 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $624.00 12/29/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS CORPORA
??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants with Moderately to Severely Active Ulcerative Colitis? No dispute reported 06/30/2026 1175421726
Principal investigator 1 Janssen Research & Development, LLC $8,181.00 12/25/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS, CORPOR
A Phase 3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol in Adults with an Open Label Study in Adolescents to Evaluate the Efficacy and Safety of Induction and Maintenance Therapy with Icotrokinra in Participants With Moderately to Severely Active Ulcerative Colitis ICONIC-UC No dispute reported 06/30/2026 1175421762
Principal investigator 1 Boehringer Ingelheim International GmbH $798.20 12/19/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695587
Principal investigator 1 Boehringer Ingelheim International GmbH $798.20 12/19/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695589
Principal investigator 1 Boehringer Ingelheim International GmbH $287.30 12/19/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695591
Principal investigator 1 Boehringer Ingelheim International GmbH $1,700.40 12/19/2025 Non-covered Recipient Entity
Clinnova
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220695647
Principal investigator 1 Boehringer Ingelheim International GmbH $14,474.20 12/19/2025 Non-covered Recipient Entity
Clinnova
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220695649
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 12/17/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695607
Principal investigator 1 Boehringer Ingelheim International GmbH $255.50 12/17/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695609
Principal investigator 1 Janssen Research & Development, LLC $28,036.00 12/15/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS, CORPOR
A Phase 3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol in Adults with an Open Label Study in Adolescents to Evaluate the Efficacy and Safety of Induction and Maintenance Therapy with Icotrokinra in Participants With Moderately to Severely Active Ulcerative Colitis ICONIC-UC No dispute reported 06/30/2026 1175421755
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $475.00 12/12/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223289650
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,171.30 12/11/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS CORPORATION
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184274614
Principal investigator 1 ABBVIE INC. $2,665.00 12/04/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202527230
Principal investigator 1 Janssen Research & Development, LLC $28,091.00 11/25/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS, CORPOR
A Phase 3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol in Adults with an Open Label Study in Adolescents to Evaluate the Efficacy and Safety of Induction and Maintenance Therapy with Icotrokinra in Participants With Moderately to Severely Active Ulcerative Colitis ICONIC-UC No dispute reported 06/30/2026 1175421768
Principal investigator 1 Boehringer Ingelheim International GmbH $163.24 11/19/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695599
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 11/19/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695601
Principal investigator 1 Boehringer Ingelheim International GmbH $401.50 11/19/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695603
Principal investigator 1 Boehringer Ingelheim International GmbH $2.00 11/19/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695605
Principal investigator 1 Boehringer Ingelheim International GmbH $99.90 11/19/2025 Non-covered Recipient Entity
Clinnova
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220695655
Principal investigator 1 Boehringer Ingelheim International GmbH $292.00 11/19/2025 Non-covered Recipient Entity
Clinnova
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220695657
Principal investigator 1 Boehringer Ingelheim International GmbH $8.00 11/19/2025 Non-covered Recipient Entity
Clinnova
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220695659
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,171.30 11/14/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS CORPORATION
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184261325
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,581.00 11/07/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS CORPORATION
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184258959
Recipient Eli Lilly and Company $388.40 11/04/2025 Covered Recipient Physician A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED STUDY OF LY4268989 (MORF-057) CO-ADMINISTERED WITH MIRIKIZUMAB IN ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1187872067
Principal investigator 1 Janssen Research & Development, LLC $1,728.00 10/31/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS CORPORA
??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants with Moderately to Severely Active Ulcerative Colitis? No dispute reported 06/30/2026 1175421678
Principal investigator 1 Janssen Research & Development, LLC $1,447.00 10/29/2025 Non-covered Recipient Entity
Clinnova Rsrch Solutions Corp.
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175170769
Principal investigator 1 Boehringer Ingelheim International GmbH $99.90 10/27/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695593
Principal investigator 1 Boehringer Ingelheim International GmbH $328.50 10/27/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695595
Principal investigator 1 Boehringer Ingelheim International GmbH $7.00 10/27/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695597
Principal investigator 1 Boehringer Ingelheim International GmbH $2,286.70 10/27/2025 Non-covered Recipient Entity
Clinnova
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220695643
Principal investigator 1 Boehringer Ingelheim International GmbH $14,474.20 10/27/2025 Non-covered Recipient Entity
Clinnova
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220695645
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 10/27/2025 Non-covered Recipient Entity
Clinnova
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220695651
Principal investigator 1 Boehringer Ingelheim International GmbH $255.50 10/27/2025 Non-covered Recipient Entity
Clinnova
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220695653
Principal investigator 1 Janssen Research & Development, LLC $2,230.00 10/27/2025 Non-covered Recipient Entity
Clinnova Rsrch Solutions Corp.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175170420
Principal investigator 1 Janssen Research & Development, LLC $1,359.00 10/27/2025 Non-covered Recipient Entity
Clinnova Rsrch Solutions Corp.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175170449
Principal investigator 1 Janssen Research & Development, LLC $1,359.00 10/27/2025 Non-covered Recipient Entity
Clinnova Rsrch Solutions Corp.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175170493
Principal investigator 1 Janssen Research & Development, LLC $184.00 10/27/2025 Non-covered Recipient Entity
Clinnova Rsrch Solutions Corp.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175170528
Principal investigator 1 Janssen Research & Development, LLC $1,602.00 10/27/2025 Non-covered Recipient Entity
Clinnova Rsrch Solutions Corp.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175170574
Principal investigator 1 Janssen Research & Development, LLC $184.00 10/27/2025 Non-covered Recipient Entity
Clinnova Rsrch Solutions Corp.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175170607
Principal investigator 1 Janssen Research & Development, LLC $184.00 10/27/2025 Non-covered Recipient Entity
Clinnova Rsrch Solutions Corp.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175170616
Principal investigator 1 Janssen Research & Development, LLC $2,230.00 10/27/2025 Non-covered Recipient Entity
Clinnova Rsrch Solutions Corp.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175170789
Principal investigator 1 Janssen Research & Development, LLC $100.00 10/23/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS CORPORA
??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants with Moderately to Severely Active Ulcerative Colitis? No dispute reported 06/30/2026 1175421721
Principal investigator 1 Janssen Research & Development, LLC $50.00 10/20/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS CORPORA
??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants with Moderately to Severely Active Ulcerative Colitis? No dispute reported 06/30/2026 1175421690
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $155.00 10/16/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS CORPORATION
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184250665
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $45.00 10/16/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS CORPORATION
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184250667
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $155.00 10/16/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS CORPORATION
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184250669
Principal investigator 1 Bausch Health US, LLC $902.50 09/30/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224837506
Principal investigator 1 Boehringer Ingelheim International GmbH $525.20 09/29/2025 Non-covered Recipient Entity
Clinnova
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220695639
Principal investigator 1 Boehringer Ingelheim International GmbH $1,700.40 09/29/2025 Non-covered Recipient Entity
Clinnova
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220695641
Principal investigator 1 Janssen Research & Development, LLC $18,107.00 09/29/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS CORPORA TION
??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants No dispute reported 06/30/2026 1175421674
Principal investigator 1 Bausch Health US, LLC $1,396.14 09/24/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224837499
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 09/24/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695585
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 09/24/2025 Non-covered Recipient Entity
Clinnova
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220695637
Principal investigator 1 Janssen Research & Development, LLC $1,048.00 09/17/2025 Non-covered Recipient Entity
Clinnova Rsrch Solutions Corp.
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175170536
Principal investigator 1 Janssen Research & Development, LLC $1,048.00 09/17/2025 Non-covered Recipient Entity
Clinnova Rsrch Solutions Corp.
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175170551
Principal investigator 1 Janssen Research & Development, LLC $1,048.00 09/17/2025 Non-covered Recipient Entity
Clinnova Rsrch Solutions Corp.
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175170648
Principal investigator 1 Janssen Research & Development, LLC $1,048.00 09/17/2025 Non-covered Recipient Entity
Clinnova Rsrch Solutions Corp.
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175170655
Principal investigator 1 Janssen Research & Development, LLC $1,447.00 09/17/2025 Non-covered Recipient Entity
Clinnova Rsrch Solutions Corp.
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175170740
Principal investigator 1 Janssen Research & Development, LLC $1,447.00 09/17/2025 Non-covered Recipient Entity
Clinnova Rsrch Solutions Corp.
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175170761
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,171.30 09/12/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS CORPORATION
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184236570
Principal investigator 1 Bausch Health US, LLC $1,619.59 09/11/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224837503
Principal investigator 1 Janssen Research & Development, LLC $50.00 09/08/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS CORPORA TION
??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants No dispute reported 06/30/2026 1175421739
Principal investigator 1 ABBVIE INC. $7,931.30 09/05/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202510160
Principal investigator 1 Janssen Research & Development, LLC $7,654.00 09/05/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS CORPORA TION
??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants No dispute reported 06/30/2026 1175421694
Principal investigator 1 ABBVIE INC. $5,330.00 09/04/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202509892
Principal investigator 1 Boehringer Ingelheim International GmbH $148.00 08/26/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695569
Principal investigator 1 Boehringer Ingelheim International GmbH $69.96 08/26/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695571
Principal investigator 1 Boehringer Ingelheim International GmbH $159.84 08/26/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695573
Principal investigator 1 Boehringer Ingelheim International GmbH $1,058.50 08/26/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695575
Principal investigator 1 Boehringer Ingelheim International GmbH $252.20 08/26/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695577
Principal investigator 1 Boehringer Ingelheim International GmbH $58.62 08/26/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695579
Principal investigator 1 Boehringer Ingelheim International GmbH $12.60 08/26/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695581
Principal investigator 1 Boehringer Ingelheim International GmbH $10.00 08/26/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695583
Principal investigator 1 ABBVIE INC. $5,265.00 08/06/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202502725
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 08/04/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695557
Principal investigator 1 Boehringer Ingelheim International GmbH $124.00 08/04/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695559
Principal investigator 1 Boehringer Ingelheim International GmbH $40.00 08/04/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695561
Principal investigator 1 Boehringer Ingelheim International GmbH $49.00 08/04/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695563
Principal investigator 1 Janssen Research & Development, LLC $2,128.00 07/31/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS CORPORA TION
??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants No dispute reported 06/30/2026 1175421667
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $155.00 07/31/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS CORPORATION
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184222830
Principal investigator 1 Boehringer Ingelheim International GmbH $14,474.20 07/30/2025 Non-covered Recipient Entity
Clinnova
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220695627
Principal investigator 1 Boehringer Ingelheim International GmbH $525.20 07/30/2025 Non-covered Recipient Entity
Clinnova
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220695629
Principal investigator 1 Boehringer Ingelheim International GmbH $1,992.90 07/30/2025 Non-covered Recipient Entity
Clinnova
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220695631
Principal investigator 1 Boehringer Ingelheim International GmbH $148.00 07/28/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695565
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 07/28/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695567
Principal investigator 1 Boehringer Ingelheim International GmbH $119.88 07/28/2025 Non-covered Recipient Entity
Clinnova
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220695633
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 07/28/2025 Non-covered Recipient Entity
Clinnova
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220695635
Principal investigator 1 Janssen Research & Development, LLC $184.00 07/28/2025 Non-covered Recipient Entity
Clinnova Rsrch Solutions Corp.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175170405
Principal investigator 1 Janssen Research & Development, LLC $1,602.00 07/28/2025 Non-covered Recipient Entity
Clinnova Rsrch Solutions Corp.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175170482
Principal investigator 1 Janssen Research & Development, LLC $184.00 07/28/2025 Non-covered Recipient Entity
Clinnova Rsrch Solutions Corp.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175170587
Principal investigator 1 Janssen Research & Development, LLC $1,955.00 07/28/2025 Non-covered Recipient Entity
Clinnova Rsrch Solutions Corp.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175170595
Principal investigator 1 Janssen Research & Development, LLC $184.00 07/28/2025 Non-covered Recipient Entity
Clinnova Rsrch Solutions Corp.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175170663
Principal investigator 1 Janssen Research & Development, LLC $1,359.00 07/28/2025 Non-covered Recipient Entity
Clinnova Rsrch Solutions Corp.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175170700
Principal investigator 1 Janssen Research & Development, LLC $1,602.00 07/28/2025 Non-covered Recipient Entity
Clinnova Rsrch Solutions Corp.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175170714
Principal investigator 1 Boehringer Ingelheim International GmbH $75.00 07/23/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695553
Principal investigator 1 Boehringer Ingelheim International GmbH $74.50 07/23/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695555
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,623.10 07/22/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS CORPORATION
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184217759
Principal investigator 1 Boehringer Ingelheim International GmbH $4,412.20 07/16/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695545
Principal investigator 1 Boehringer Ingelheim International GmbH $4,282.20 07/16/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695547
Principal investigator 1 Boehringer Ingelheim International GmbH $13,699.40 07/16/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695549
Principal investigator 1 Boehringer Ingelheim International GmbH $4,412.20 07/16/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695551
Principal investigator 1 Janssen Research & Development, LLC $75.00 07/10/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS CORPORA TION
??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants No dispute reported 06/30/2026 1175421708
Principal investigator 1 ABBVIE INC. $7,931.30 07/09/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202497634
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,171.30 07/04/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS CORPORATION
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184212847
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $175.00 07/04/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS CORPORATION
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184212849
Principal investigator 1 ABBVIE INC. $6,045.00 07/02/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202494957
Principal investigator 1 Boehringer Ingelheim International GmbH $15,973.10 06/30/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695477
Principal investigator 1 Boehringer Ingelheim International GmbH $798.20 06/30/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695479
Principal investigator 1 Boehringer Ingelheim International GmbH $3,238.30 06/30/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695481
Principal investigator 1 Boehringer Ingelheim International GmbH $798.20 06/30/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695483
Principal investigator 1 Boehringer Ingelheim International GmbH $798.20 06/30/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695485
Principal investigator 1 Boehringer Ingelheim International GmbH $11,359.40 06/30/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695487
Principal investigator 1 Boehringer Ingelheim International GmbH $2,470.00 06/30/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695489
Principal investigator 1 Boehringer Ingelheim International GmbH $2,762.50 06/30/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695491
Principal investigator 1 Boehringer Ingelheim International GmbH $3,108.30 06/30/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695493
Principal investigator 1 Boehringer Ingelheim International GmbH $798.20 06/30/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695495
Principal investigator 1 Boehringer Ingelheim International GmbH $2,340.00 06/30/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695497
Principal investigator 1 Boehringer Ingelheim International GmbH $15,685.80 06/30/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695499
Principal investigator 1 Boehringer Ingelheim International GmbH $3,922.10 06/30/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695501
Principal investigator 1 Boehringer Ingelheim International GmbH $2,470.00 06/30/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695503
Principal investigator 1 Boehringer Ingelheim International GmbH $2,340.00 06/30/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695505
Principal investigator 1 Boehringer Ingelheim International GmbH $2,632.50 06/30/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695507
Principal investigator 1 Boehringer Ingelheim International GmbH $2,470.00 06/30/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695509
Principal investigator 1 Boehringer Ingelheim International GmbH $2,340.00 06/30/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695511
Principal investigator 1 Boehringer Ingelheim International GmbH $798.20 06/30/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695513
Principal investigator 1 Janssen Research & Development, LLC $2,678.00 06/30/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS CORPORA TION
??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Pa No dispute reported 06/30/2026 1175421711
Principal investigator 1 Boehringer Ingelheim International GmbH $59.94 06/24/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695541
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 06/24/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695543
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $200.00 06/12/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS CORPORATION
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184206239
Principal investigator 1 ABBVIE INC. $682.50 06/11/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202490835
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $475.00 06/06/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223280830
Principal investigator 1 Bausch Health US, LLC $411.28 06/05/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224837525
Principal investigator 1 Boehringer Ingelheim International GmbH $798.20 05/28/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695515
Principal investigator 1 Boehringer Ingelheim International GmbH $2,470.00 05/28/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695517
Principal investigator 1 Boehringer Ingelheim International GmbH $2,340.00 05/28/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695519
Principal investigator 1 Boehringer Ingelheim International GmbH $3,238.30 05/28/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695521
Principal investigator 1 Boehringer Ingelheim International GmbH $3,108.30 05/28/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695523
Principal investigator 1 Boehringer Ingelheim International GmbH $798.20 05/28/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695525
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,171.30 05/28/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS CORPORATION
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184198873
Principal investigator 1 Boehringer Ingelheim International GmbH $128.26 05/27/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695529
Principal investigator 1 Boehringer Ingelheim International GmbH $159.84 05/27/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695531
Principal investigator 1 Boehringer Ingelheim International GmbH $292.00 05/27/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695533
Principal investigator 1 Boehringer Ingelheim International GmbH $252.20 05/27/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695535
Principal investigator 1 Boehringer Ingelheim International GmbH $29.31 05/27/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695537
Principal investigator 1 Boehringer Ingelheim International GmbH $6.00 05/27/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695539
Principal investigator 1 Boehringer Ingelheim International GmbH $46.64 05/27/2025 Non-covered Recipient Entity
Clinnova
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220695619
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 05/27/2025 Non-covered Recipient Entity
Clinnova
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220695621
Principal investigator 1 Boehringer Ingelheim International GmbH $401.50 05/27/2025 Non-covered Recipient Entity
Clinnova
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220695623
Principal investigator 1 Boehringer Ingelheim International GmbH $4.00 05/27/2025 Non-covered Recipient Entity
Clinnova
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220695625
Principal investigator 1 Janssen Research & Development, LLC $7,534.00 05/23/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS CORPORA TION
??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants No dispute reported 06/30/2026 1175421745
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $882.30 05/15/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS CORPORATION
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184194627
Principal investigator 1 Bausch Health US, LLC $4,775.56 05/13/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224837521
Principal investigator 1 Janssen Research & Development, LLC $1,359.00 05/12/2025 Non-covered Recipient Entity
Clinnova Rsrch Solutions Corp.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175170397
Principal investigator 1 Janssen Research & Development, LLC $1,359.00 05/12/2025 Non-covered Recipient Entity
Clinnova Rsrch Solutions Corp.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175170412
Principal investigator 1 Janssen Research & Development, LLC $1,602.00 05/12/2025 Non-covered Recipient Entity
Clinnova Rsrch Solutions Corp.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175170441
Principal investigator 1 Janssen Research & Development, LLC $1,602.00 05/12/2025 Non-covered Recipient Entity
Clinnova Rsrch Solutions Corp.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175170456
Principal investigator 1 Janssen Research & Development, LLC $184.00 05/12/2025 Non-covered Recipient Entity
Clinnova Rsrch Solutions Corp.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175170511
Principal investigator 1 Janssen Research & Development, LLC $184.00 05/12/2025 Non-covered Recipient Entity
Clinnova Rsrch Solutions Corp.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175170543
Principal investigator 1 Janssen Research & Development, LLC $184.00 05/12/2025 Non-covered Recipient Entity
Clinnova Rsrch Solutions Corp.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175170559
Principal investigator 1 Janssen Research & Development, LLC $184.00 05/12/2025 Non-covered Recipient Entity
Clinnova Rsrch Solutions Corp.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175170630
Principal investigator 1 Janssen Research & Development, LLC $1,955.00 05/12/2025 Non-covered Recipient Entity
Clinnova Rsrch Solutions Corp.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175170677
Principal investigator 1 Janssen Research & Development, LLC $184.00 05/12/2025 Non-covered Recipient Entity
Clinnova Rsrch Solutions Corp.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175170778
Principal investigator 1 AstraZeneca Pharmaceuticals LP $11,106.03 04/30/2025 Non-covered Recipient Entity
TEXAS ARTHRITIS CENTER, PA
A Randomised, Double-blind, Placebo-controlled, Multi-centre Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 in Participants with Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) with Fibrosis Who Are Carriers of the PNPLA3 rs738409 148M Risk Allele No dispute reported 06/30/2026 1185552787
Principal investigator 1 Boehringer Ingelheim International GmbH $798.20 04/28/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695441
Principal investigator 1 Boehringer Ingelheim International GmbH $4,228.90 04/28/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695443
Principal investigator 1 Boehringer Ingelheim International GmbH $798.20 04/28/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695445
Principal investigator 1 Boehringer Ingelheim International GmbH $4,228.90 04/28/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695447
Principal investigator 1 Boehringer Ingelheim International GmbH $3,448.90 04/28/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695449
Principal investigator 1 Boehringer Ingelheim International GmbH $4,228.90 04/28/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695451
Principal investigator 1 Boehringer Ingelheim International GmbH $3,922.10 04/28/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695453
Principal investigator 1 Boehringer Ingelheim International GmbH $15,973.10 04/28/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695455
Principal investigator 1 Boehringer Ingelheim International GmbH $15,685.80 04/28/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695457
Principal investigator 1 Boehringer Ingelheim International GmbH $13,646.10 04/28/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695459
Principal investigator 1 Boehringer Ingelheim International GmbH $9,535.50 04/28/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695461
Principal investigator 1 Boehringer Ingelheim International GmbH $2,632.50 04/28/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695463
Principal investigator 1 Boehringer Ingelheim International GmbH $2,762.50 04/28/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695465
Principal investigator 1 Boehringer Ingelheim International GmbH $4,358.90 04/28/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695467
Principal investigator 1 Boehringer Ingelheim International GmbH $4,228.90 04/28/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695471
Principal investigator 1 Boehringer Ingelheim International GmbH $11,359.40 04/28/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695473
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,581.00 04/28/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS CORPORATION
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184190759
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $175.00 04/28/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS CORPORATION
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184190761
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $155.00 04/28/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS CORPORATION
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184190763
Principal investigator 1 Boehringer Ingelheim International GmbH $151.32 04/23/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695527
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 04/23/2025 Non-covered Recipient Entity
Clinnova
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220695615
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 04/23/2025 Non-covered Recipient Entity
Clinnova
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220695617
Principal investigator 1 Boehringer Ingelheim International GmbH $4.50 04/22/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695469
Principal investigator 1 Boehringer Ingelheim International GmbH $4.50 04/22/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695475
Principal investigator 1 Janssen Research & Development, LLC $50.00 04/21/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS CORPORA TION
??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants No dispute reported 06/30/2026 1175421750
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $475.00 04/09/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223277678
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,171.30 04/01/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS CORPORATION
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184180824
Principal investigator 1 Janssen Research & Development, LLC $5,406.00 03/31/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS CORPORA TION
??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants No dispute reported 06/30/2026 1175421733
Principal investigator 1 Boehringer Ingelheim International GmbH $3,922.10 03/27/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695425
Principal investigator 1 Boehringer Ingelheim International GmbH $15,685.80 03/27/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695427
Principal investigator 1 Eli Lilly and Company $29,899.80 03/26/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS CORPORATION
AN ADAPTIVE, DOSE-RANGING, PHASE 2 STUDY OF ELTREKIBART GIVEN ALONE OR IN COMBINATION WITH MIRIKIZUMAB FOR THE TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1187883122
Principal investigator 1 Boehringer Ingelheim International GmbH $79.92 03/25/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695439
Principal investigator 1 Boehringer Ingelheim International GmbH $438.00 03/25/2025 Non-covered Recipient Entity
Clinnova
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220695611
Principal investigator 1 Boehringer Ingelheim International GmbH $2.00 03/25/2025 Non-covered Recipient Entity
Clinnova
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220695613
Principal investigator 1 Celgene Corporation $5,000.00 03/25/2025 Non-covered Recipient Entity
Clinnova Research Solutions
A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 1222306587
Principal investigator 1 Bausch Health US, LLC $5,854.97 03/11/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224837513
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,053.60 03/11/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS CORPORATION
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184170880
Principal investigator 1 Janssen Research & Development, LLC $2,728.00 03/06/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS CORPORA TION
??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants No dispute reported 06/30/2026 1175421683
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $175.00 03/04/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS CORPORATION
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184156742
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $45.00 03/04/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS CORPORATION
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184156744
Principal investigator 1 Janssen Research & Development, LLC $335.00 02/26/2025 Non-covered Recipient Entity
Clinnova Rsrch Solutions Corp.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175170428
Principal investigator 1 Janssen Research & Development, LLC $1,602.00 02/26/2025 Non-covered Recipient Entity
Clinnova Rsrch Solutions Corp.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175170461
Principal investigator 1 Janssen Research & Development, LLC $184.00 02/26/2025 Non-covered Recipient Entity
Clinnova Rsrch Solutions Corp.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175170475
Principal investigator 1 Janssen Research & Development, LLC $184.00 02/26/2025 Non-covered Recipient Entity
Clinnova Rsrch Solutions Corp.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175170501
Principal investigator 1 Janssen Research & Development, LLC $1,955.00 02/26/2025 Non-covered Recipient Entity
Clinnova Rsrch Solutions Corp.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175170518
Principal investigator 1 Janssen Research & Development, LLC $335.00 02/26/2025 Non-covered Recipient Entity
Clinnova Rsrch Solutions Corp.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175170624
Principal investigator 1 Janssen Research & Development, LLC $1,955.00 02/26/2025 Non-covered Recipient Entity
Clinnova Rsrch Solutions Corp.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175170671
Principal investigator 1 Janssen Research & Development, LLC $184.00 02/26/2025 Non-covered Recipient Entity
Clinnova Rsrch Solutions Corp.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175170692
Principal investigator 1 Janssen Research & Development, LLC $1,602.00 02/26/2025 Non-covered Recipient Entity
Clinnova Rsrch Solutions Corp.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175170708
Principal investigator 1 Janssen Research & Development, LLC $184.00 02/26/2025 Non-covered Recipient Entity
Clinnova Rsrch Solutions Corp.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175170722
Principal investigator 1 Janssen Research & Development, LLC $184.00 02/26/2025 Non-covered Recipient Entity
Clinnova Rsrch Solutions Corp.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175170730
Principal investigator 1 Janssen Research & Development, LLC $1,359.00 02/26/2025 Non-covered Recipient Entity
Clinnova Rsrch Solutions Corp.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175170748
Principal investigator 1 Boehringer Ingelheim International GmbH $104.94 02/25/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695433
Principal investigator 1 Boehringer Ingelheim International GmbH $328.50 02/25/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695435
Principal investigator 1 Boehringer Ingelheim International GmbH $5.00 02/25/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695437
Principal investigator 1 Janssen Research & Development, LLC $50.00 02/24/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS CORPORA TION
??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants No dispute reported 06/30/2026 1175421660
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,823.90 02/18/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS CORPORATION
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184154210
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $45.00 02/18/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS CORPORATION
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184154212
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $122.60 02/18/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS CORPORATION
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184154214
Principal investigator 1 Janssen Research & Development, LLC $672.00 02/17/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS CORPORA TION
??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants No dispute reported 06/30/2026 1175421701
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,910.95 02/05/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS CORPORATION
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184152458
Principal investigator 1 AstraZeneca Pharmaceuticals LP $42,096.59 01/31/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS
A Randomised, Double-blind, Placebo-controlled, Multi-centre Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 in Participants with Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) with Fibrosis Who Are Carriers of the PNPLA3 rs738409 148M Risk Allele No dispute reported 06/30/2026 1185552785
Principal investigator 1 Janssen Research & Development, LLC $2,678.00 01/31/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS CORPORA TION
??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants No dispute reported 06/30/2026 1175421717
Principal investigator 1 ABBVIE INC. $11,000.00 01/28/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS
M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202441610
Principal investigator 1 ABBVIE INC. $9,250.00 01/28/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS
M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202441613
Principal investigator 1 Bausch Health US, LLC $1,262.39 01/28/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224837509
Principal investigator 1 Boehringer Ingelheim International GmbH $59.94 01/27/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695429
Principal investigator 1 Boehringer Ingelheim International GmbH $255.50 01/27/2025 Non-covered Recipient Entity
Clinnova
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220695431
Principal investigator 1 Bausch Health US, LLC $411.28 01/13/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224837517
Principal investigator 1 Celgene Corporation $705.16 01/01/2025 Non-covered Recipient Entity
OC Gastrocare
Induction Study #1 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 1222306677